Published in J Infect on February 04, 2010
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother (2010) 1.35
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis (2013) 1.34
Pathology of Fungal Rhinosinusitis: A Review. Head Neck Pathol (2016) 1.12
The challenge of managing fusariosis. Virulence (2011) 1.10
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2013) 0.96
European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis (2014) 0.92
Amphotericin B and voriconazole susceptibility profiles for the Fusarium solani species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology. Eur J Clin Microbiol Infect Dis (2011) 0.86
Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents (2012) 0.86
Invasive fungal infections in transplant recipients. Ther Adv Infect Dis (2013) 0.85
Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis? J Infect (2012) 0.81
Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience. Open Forum Infect Dis (2015) 0.81
The role of mycelium production and a MAPK-mediated immune response in the C. elegans-Fusarium model system. Med Mycol (2012) 0.79
Antimold Prophylaxis May Reduce the Risk of Invasive Fusariosis in Hematologic Patients with Superficial Skin Lesions with Positive Culture for Fusarium. Antimicrob Agents Chemother (2016) 0.75
Disseminated fusariosis with immune reconstitution syndrome and cracking mycotic aortic aneurysm in a 55-year-old patient with acute myeloid leukaemia. BMJ Case Rep (2013) 0.75
Successful Treatment of Disseminated Fusariosis with the Combination of Voriconazole and Liposomal Amphotericin B. Turk J Haematol (2016) 0.75
Fatal disseminated fusarium infection in a human immunodeficiency virus positive patient. Case Rep Infect Dis (2013) 0.75
Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant. Exp Ther Med (2016) 0.75
Skin nodules in a patient with acute lymphoblastic leukaemia. BMJ Case Rep (2014) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis (2008) 2.65
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica (2006) 2.41
Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am (2006) 2.26
Antifungal drug resistance of pathogenic fungi. Lancet (2002) 2.20
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Glucocorticoids and invasive fungal infections. Lancet (2003) 2.11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis (2005) 2.06
Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis (2012) 1.96
Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol (2003) 1.96
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol (2012) 1.93
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect (2011) 1.90
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs (2003) 1.86
Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev (2011) 1.82
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol (2003) 1.73
Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer (2009) 1.69
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.69
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect (2010) 1.67
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
Breast implant infections: is cefazolin enough? Plast Reconstr Surg (2010) 1.67
Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis (2008) 1.64
Tuberculosis: a benign impostor. AJR Am J Roentgenol (2010) 1.62
Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis (2010) 1.60
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med (2002) 1.60
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis (2010) 1.58
Pulmonary mucormycosis. Semin Respir Crit Care Med (2011) 1.58
Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis (2008) 1.57
Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc (2008) 1.56
Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis (2010) 1.55
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A (2008) 1.54
Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) (2003) 1.51
Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood (2004) 1.51
How I treat mucormycosis. Blood (2011) 1.51
The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis (2011) 1.49
Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis (2013) 1.49
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2002) 1.47
Aminopeptidase N inhibitors and SARS. Lancet (2003) 1.47
Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis (2005) 1.47
Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis (2006) 1.46
Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis (2006) 1.46
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis (2012) 1.45
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis (2009) 1.44
Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis (2014) 1.42
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood (2004) 1.42
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Detection of gliotoxin in experimental and human aspergillosis. Infect Immun (2005) 1.38
Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol (2009) 1.36
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis (2002) 1.36
Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother (2002) 1.36
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Isogenic auxotrophic mutant strains in the Aspergillus fumigatus genome reference strain AF293. Arch Microbiol (2004) 1.34
Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J Antimicrob Chemother (2004) 1.33
Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother (2003) 1.33
Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis (2009) 1.33
Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol (2008) 1.33